L’Oréal has announced a strategic agreement to acquire Medik8, a leading British skincare brand known for its premium clinical products. This acquisition represents a significant step in L’Oréal’s global expansion plans. Under the agreement, Medik8’s founder, its current management team, and private equity partner Inflexion will remain involved in the business’s operations.
Medik8, recognized for its B Corp certification, is a results-driven skincare brand that has established a strong presence in Europe, Australia, and the United States. The partnership with L’Oréal marks the beginning of a new growth phase for Medik8, as it aims to enhance its innovation capabilities and expand its customer base worldwide.
Simon Coble, CEO of Medik8, expressed excitement about the acquisition: “This is an exciting day for our brand. With the support of Inflexion, we’ve shown Medik8 to be a formidable force, delivering high-quality, clinically proven results. Now, with L’Oréal’s support, we can take the brand to new heights, further strengthening our innovation and reaching more customers globally.”
Medik8 was founded in 2009 by scientist Elliot Isaacs and has since become a leader in active skincare. The brand is known for its high-performance products, including the popular Crystal Retinal serum and its CSA Philosophy—Vitamin C and sunscreen for the day, and Vitamin A for the night. Medik8 products are sold through professional clinics, pharmacies, the brand’s own direct-to-consumer platform, and major retailers like Space NK, Sephora UK, and Harrods. All products are formulated and manufactured in-house at its Innovation Centre in the UK.
Elliot Isaacs, Founder of Medik8, commented, “Medik8 was created to prove that skincare can deliver real results without compromise. Our focus on science, customer experience, and sustainability has been key to our success. I’m thrilled that Medik8 will now be part of L’Oréal, a partner that shares our vision and gives us the opportunity to scale globally.”
Cyril Chapuy, President of L’Oréal LUXE, added, “We are excited to welcome Medik8 to the L’Oréal family. The brand’s premium skincare range, which combines proven efficacy with accessibility, is a perfect complement to our existing portfolio. We believe in Medik8’s global potential and look forward to growing the brand worldwide.”
Tom Pemberton, Partner and Head of Consumer at Inflexion, shared his pride in Medik8’s success, stating, “Medik8 has always stood out as a unique and differentiated business. I am proud of what we’ve accomplished and look forward to working with L’Oréal in the next chapter of this journey.”
The deal is expected to close in the coming months, pending regulatory approvals and other standard conditions.
Related Topics:
